GSK to ‘phase out’ manufacture of active ingredients at UK plant, 200 jobs cut

By Ben Hargreaves

- Last updated on GMT

(Image: Getty/Sopone Nawoot)
(Image: Getty/Sopone Nawoot)

Related tags Gsk Antibiotics

Following a review of its Ulverston site, GSK announced at the end of last week it would shed positions related to the manufacture of active ingredients for sterile injections.

The decision will see approximately 200 positions cut away at the facility in Cumbria, UK. However, the company stated it would maintain its cephalosporins antibiotics business, which will see 150 roles kept on at the same site.

A spokesperson for GSK told us, “Following a review of our cephalosporins antibiotics business announced last year, we have decided to retain this business, which continues to grow strongly, and redesign the supply chain to improve efficiency and reliability.However, we have decided to phase out the manufacturing of active ingredients for sterile injections at our Ulverston site.”

GSK confirmed the announcement would have no impact on the supply of products currently produced at the facility.

The decision has made for a tumultuous time for workers at the facility – as recently as 2014, there had been major plans​ to create a biomanufacturing facility alongside its existing presence in Ulverston, only for this to be withdrawn last year​.

At the time, the company stressed the decision was not as a result of the Brexit referendum and, in an emailed statement, GSK reaffirmed that this was also the case in this most recent move.

The Ulverston announcement is the most recent restructuring news for GSK, following site closures in Ireland​ and Bangladesh​ earlier this year.

Related news

Show more

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Manufacturing Drugs with Highly Potent APIs

Manufacturing Drugs with Highly Potent APIs

Content provided by Altasciences | 28-Sep-2023 | White Paper

In this issue of The Altascientist, we examine the critical considerations for the safe and compliant manufacture of drugs with highly potent APIs (HPAPIs),...